IndustryCompany release
CytoSorbents reaches operating cash flow breakeven in Q3 as operating loss narrows 59%
🇺🇸 Cytosorbents Corp (CTSO) · Thu 19 Nov 2026
The blood purification company reports 3% revenue growth to $9.7M, a 75% gross margin and lower costs, alongside an update on its DrugSorb-ATR US market pursuit.
CytoSorbents Corp has reported results for the third quarter of 2026, which ended on 30 September. Revenue rose 3% to $9.7M, and the company said its operating loss narrowed by 59%.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Cytosorbents Corp ↗
Article written by VigiEye from the official source (Cytosorbents Corp). Claims are the company's own. AI-assisted; check the source before acting.
More Industry
All →
Emmaus Q3 revenue falls to $1.9M after Endari licence; going-concern doubt flagged
🇺🇸 Emmaus Life Sciences, Inc. (EMMA) · Thu 19 Nov 2026
Prenetics widens H2 EBITDA loss guidance to $30-35M as IM8 spending rises
Prenetics Global Ltd (PRE) · Wed 18 Nov 2026
Quantum-Si detects all 20 amino acids at single-molecule level on Proteus platform
🇺🇸 Quantum-Si Inc (QSI) · Wed 18 Nov 2026
NeOnc to meet FDA in January 2027 on NEO100 accelerated approval path
🇺🇸 Neonc Technologies Holdings, Inc. (NTHI) · Wed 18 Nov 2026
newcleo reports Q3 revenue of about €10M and €233.4M cash as PRECURSOR e-core completed
newcleo plc (NWCL) · Wed 18 Nov 2026
Iridex cuts 2026 revenue guidance to $46-48M after 19% third-quarter sales drop
🇺🇸 Iridex Corp (IRIX) · Tue 17 Nov 2026